Company profile
GeoVax Labs, Inc.
NASDAQ:GOVXBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01378156 | phase1 | completed | 2010-06-01 | 2014-05-01 | GeoVax, Inc. | A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART |
| NCT04639466 | phase1_2 | completed | 2020-11-19 | 2025-10-31 | GeoVax, Inc. | A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection |
| NCT04977024 | phase2 | active_not_recruiting | 2021-09-27 | 2026-12-31 | GeoVax, Inc. | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
| NCT03754933 | phase1_2 | completed | 2019-02-11 | 2023-12-29 | GeoVax, Inc. | Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer |
FDA applications (0)
No records yet.